Medicare AdvantageCoverageMedium impact
MA08.181, Zolbetuximab-clzb (Vyloy®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.181 has been established for Zolbetuximab-clzb (Vyloy®), a pharmacy benefit drug. This creates coverage guidelines for this newly approved medication under Medicare Advantage plans.
Action Required
By April 21, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Zolbetuximab-clzb (Vyloy®). Update pharmacy benefit verification processes to include this new drug coverage under Medicare Advantage plans.